Gary Zweiger

Akadeum Life Sciences® has developed a next generation platform that solves long-standing problems across cell therapy and other research, diagnostic and therapeutic markets. The proprietary buoyant microbubble technology platform addresses the need for high cell quality, scalability, time and workflow that current magnetic particle-based products commonly used in cell therapy manufacturing and research can’t address. The Company has several GMP grade and Clinical Ready kits to enable each stage of cell therapy manufacturers pipeline. Harnessing the microbubble capability, the Alerion™ Microbubble Cell Separation System enables cell isolation from tens of billions of cells in apheresis material in under an hour, significantly expanding capacity of manufacturers. Akadeum is currently working with some of the largest corporations and forward-thinking leaders in the industry. The power of the Akadeum microbubble platform is an elegant and easy-to-use technology that can enable faster, more accurate, and scalable workflows to improve human health. Better Isolations. Healthier Cells.

Mission Bio is a company of passionate people dedicated to solving complex biological problems with precision engineering, innovative biochemistry, and supported bioinformatics. In 2014, the company was spun out of Adam Abate’s lab for high-throughput biology at the University of California, San Francisco (UCSF). Mission Bio’s precision genomics platform is based on the pioneering droplet microfluidics work of Abate and his team. Our mission is to help researchers and clinicians unlock single-cell biology to enable the discovery, development, and delivery of precision medicine. Visit missionbio.com to learn more.

Cota Capital is an early-stage investment firm that builds and invests in technology companies addressing “Net New” challenges in the enterprise. Cota believes knowledge is the true capital, and the firm leverages its deep enterprise expertise, global network of industry leaders, and systematic investment rigor to empower founders to build transformative businesses. Founded in 2015, Cota is an SEC-registered investment advisor headquartered in San Francisco. For more information, visit www.cotacapital.com. The views expressed here are independent views of the individual presenters or authors and are not the views of Cota Capital or its affiliates. This content is provided for informational purposes only, and should not be relied upon as legal, business, investment, or tax advice. References to any securities are for illustrative purposes only and do not constitute an investment recommendation or offer to provide investment advisory services. Furthermore, this content is not directed at nor intended for use by any investors or prospective investors, and may not under any circumstances be relied upon when making a decision to invest in any fund managed by Cota Capital. PLEASE SEE MORE HERE: https://www.cotacapital.com/disclosures/

Akadeum Life Sciences® has developed a next generation platform that solves long-standing problems across cell therapy and other research, diagnostic and therapeutic markets. The proprietary buoyant microbubble technology platform addresses the need for high cell quality, scalability, time and workflow that current magnetic particle-based products commonly used in cell therapy manufacturing and research can’t address. The Company has several GMP grade and Clinical Ready kits to enable each stage of cell therapy manufacturers pipeline. Harnessing the microbubble capability, the Alerion™ Microbubble Cell Separation System enables cell isolation from tens of billions of cells in apheresis material in under an hour, significantly expanding capacity of manufacturers. Akadeum is currently working with some of the largest corporations and forward-thinking leaders in the industry. The power of the Akadeum microbubble platform is an elegant and easy-to-use technology that can enable faster, more accurate, and scalable workflows to improve human health. Better Isolations. Healthier Cells.

Mission Bio is a company of passionate people dedicated to solving complex biological problems with precision engineering, innovative biochemistry, and supported bioinformatics. In 2014, the company was spun out of Adam Abate’s lab for high-throughput biology at the University of California, San Francisco (UCSF). Mission Bio’s precision genomics platform is based on the pioneering droplet microfluidics work of Abate and his team. Our mission is to help researchers and clinicians unlock single-cell biology to enable the discovery, development, and delivery of precision medicine. Visit missionbio.com to learn more.